784-P: Once-Weekly Semaglutide in Patients with Peripheral Arterial Disease and Type 2 Diabetes—Comorbidities and Concomitant Medications from the STRIDE Trial

医学 内科学 2型糖尿病 赛马鲁肽 心脏病学 人口 跛行 糖尿病 间歇性跛行 临床终点 心力衰竭 物理疗法 随机对照试验 外科 动脉疾病 血管疾病 内分泌学 利拉鲁肽 环境卫生
作者
Neda Rasouli,Andrei‐Mircea Catarig,Yasemin Hansen,Kim Houlind,CHETHANA RAMESH,Bernhard Ludvik,Joakim Nordanstig,HARALD SOURIJ,Subodh Verma,MARC P. BONACA
出处
期刊:Diabetes [American Diabetes Association]
卷期号:73 (Supplement_1)
标识
DOI:10.2337/db24-784-p
摘要

Lower extremity peripheral arterial disease (PAD) is caused by atherosclerosis of leg arteries and may result in severe functional impairment. People with type 2 diabetes (T2D) are at higher risk of developing PAD than those without T2D. We present baseline data from STRIDE, a phase 3 trial investigating functional outcomes of semaglutide treatment in patients with PAD and T2D. STRIDE enrolled 792 patients with PAD (Fontaine IIa claudication) and T2D who were randomized to either 1 mg once-weekly subcutaneous semaglutide or placebo for 52 weeks. The primary outcome is change in maximum walking distance on a constant load treadmill. Baseline characteristics, comorbidities and medications were recorded. Median age was 68, 75.4% male, a median duration of T2D of 12 years, mean HbA1c 7.3% and LDL-C 2.0 mmol/L. CVD related history included: hypertension (87.9%), coronary disease (42.4%), coronary revascularization (31.4%), MI (18.7%), coronary artery stenosis >50% (27.5%), stroke (6.4%), transient ischemic attack (3.9%), chronic heart failure (13.6%), and chronic kidney disease (15.8%). More than a third were on SGLT2is. Baseline medications are shown in table 1. We highlight the high CVD burden and the baseline medications of patients in STRIDE, representing a study population with multiple comorbid risk factors and reasonably well controlled T2D. Disclosure N. Rasouli: Advisory Panel; Eli Lilly and Company, Novo Nordisk. Research Support; Novo Nordisk. A. Catarig: Employee; Novo Nordisk A/S. Stock/Shareholder; Novo Nordisk A/S. Y. Hansen: Employee; Novo Nordisk A/S. Stock/Shareholder; Novo Nordisk A/S. K. Houlind: Consultant; LeMaitre. C. Ramesh: None. B. Ludvik: Speaker's Bureau; Novo Nordisk. Research Support; Lilly Diabetes. Speaker's Bureau; Boehringer-Ingelheim. Research Support; Bayer Inc. Speaker's Bureau; AstraZeneca. Research Support; Lilly Diabetes, Novo Nordisk, Boehringer-Ingelheim. Advisory Panel; Novo Nordisk, Lilly Diabetes. J. Nordanstig: Advisory Panel; AstraZeneca, Bayer Inc. Research Support; Artivion. H. Sourij: Advisory Panel; Amarin Corporation. Speaker's Bureau; Amgen Inc., Amarin Corporation, Bayer Inc. Advisory Panel; Boehringer-Ingelheim. Speaker's Bureau; Boehringer-Ingelheim. Research Support; Boehringer-Ingelheim. Advisory Panel; Eli Lilly and Company. Research Support; Eli Lilly and Company. Speaker's Bureau; Eli Lilly and Company. Advisory Panel; Novartis AG. Speaker's Bureau; Novartis AG. Advisory Panel; Novo Nordisk. Research Support; Novo Nordisk. Speaker's Bureau; Novo Nordisk. Research Support; Sanofi. Speaker's Bureau; Sanofi. Consultant; K:Businesscom. S. Verma: Other Relationship; Amarin Corporation, Amgen Inc., AstraZeneca, Bayer Inc., Boehringer-Ingelheim, Canadian Medical and Surgical Knowledge Translation Research Group, Eli Lilly and Company, HLS Therapeutics Inc., Janssen Pharmaceuticals, Inc., Novartis AG, Novo Nordisk, Pfizer Inc., PhaseBio Pharmaceuticals, Inc., S&L Solutions Event Management, Sanofi. M.P. Bonaca: Other Relationship; CPC Clinical Research.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wxm的应助被xiaochenxiaochen采纳,获得10
刚刚
刚刚
刚刚
研友_5Zl9D8发布了新的文献求助10
刚刚
平淡寒烟完成签到 ,获得积分10
1秒前
1秒前
1秒前
悠悠发布了新的文献求助10
1秒前
郭娅楠发布了新的文献求助10
2秒前
2秒前
yaya完成签到,获得积分20
2秒前
2秒前
2秒前
小学生发布了新的文献求助10
3秒前
Akim的应助被来一杯忌廉采纳,获得30
3秒前
Qawsed完成签到,获得积分10
3秒前
4秒前
黑皮鞋发布了新的文献求助10
4秒前
白白完成签到,获得积分20
4秒前
辞冷完成签到,获得积分20
4秒前
丘比特的应助被小泽采纳,获得10
5秒前
5秒前
5秒前
孟佳完成签到 ,获得积分10
5秒前
6秒前
cjg发布了新的文献求助10
6秒前
领导范儿的应助被201314zlj君采纳,获得10
6秒前
6秒前
李兴月完成签到,获得积分10
6秒前
6秒前
ayeben发布了新的文献求助10
6秒前
6秒前
Qawsed发布了新的文献求助30
7秒前
7秒前
8秒前
CACT完成签到,获得积分10
8秒前
彭超完成签到,获得积分10
9秒前
主要级别后卫完成签到,获得积分10
9秒前
唐唐发布了新的文献求助10
9秒前
平淡语薇完成签到,获得积分20
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8176102
求助须知:如何正确求助?哪些是违规求助? 9567588
关于积分的说明 21793477
捐赠科研通 7770603
什么是DOI,文献DOI怎么找? 3431969
关于科研通互助平台的介绍 2556294
邀请新用户注册赠送积分活动 2477522